Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Share-based compensation expense

Asset impairment and restructuring costs

Expected credit losses on financial assets and related charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Canopy Growth

Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Canopy Growth Corporation (CGC) closed the most recent trading day at $4.79, moving -0.83% from the previous trading session.

Canopy Growth Corporation (CGC) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Aurora Cannabis

Cronos Group

GrowGeneration Corp

OrganiGram Holdings Inc.

SNDL Inc.

Tilray Brands

Given recent news items regarding the federal legalization of cannabis, you may think now is the time to be thinking about which cannabis stocks to buy, not which cannabis stocks to sell. Yes, the release of a letter from the U.S. Department of Health and Human Services, recommending that marijuana be rescheduled as a Schedule III drug, may be seen as signs of marijuana legalization progress.

7 Cannabis Stocks to Sell as the Industry Faces Legal Uncertainty in 2024

SMITHS FALLS, ON , Jan. 26, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal year 2024 ended December 31, 2023 before financial markets open on February 9, 2024. Following the release of its third quarter fiscal year 2024 financial results, Canopy Growth will host an audio webcast with David Klein, CEO and Judy Hong, CFO on February 9, at 10AM  Eastern Time.

Canopy Growth to Report Third Quarter Fiscal 2024 Financial Results on February 9, 2024

Canopy Growth's cash balance has fallen sharply in just six months. The company's rate of cash burn implies it must raise more money to keep the business afloat.

What Would a Cash Crunch for Canopy Growth Mean for Investors?

SMITHS FALLS, ON , Jan. 24, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), a world-leading diversified cannabis company, today announced the introduction of new product offerings across the Company's adult use and medical cannabis portfolio, including new Tweed softgels and oils featuring minor cannabinoids, a large format flower offering from Tweed, as well as new medical exclusive pre-roll products from 7ACRES and Spectrum Therapeutics. "In addition to launching new flower products, we're making it easier to access CBD and minor cannabinoids in convenient oil and softgel formats to support wellness-minded consumers looking to start the year feeling their best," said Dave Paterson, President, Canada, Canopy Growth.

CANOPY GROWTH KICKS OFF THE NEW YEAR WITH NEW PRODUCTS FROM TWEED, 7ACRES, AND SPECTRUM THERAPEUTICS

Scotts Miracle-Gro

With almost the first month of 2024 gone legal cannabis is put on the front lines once again. Over the next several months we will see more states try to not only pass legalization measures but improve upon existing laws. Although cannabis is still federally illegal more than half of the US has legalized cannabis in some form. Whether it is a recreational market or a medical market being able to operate legally is a major win. Yet it is only one of the many pieces to the framework of legal cannabis.

This Is Why Marijuana Stocks Recover From New Cannabis Laws

Canopy Growth Corporation (CGC) reachead $4.41 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.

Canopy Growth Corporation (CGC) Outperforms Broader Market: What You Need to Know

Cannabis businesses could soon grow quickly once again. Canopy Growth is working to become more efficient.

Better Cannabis Stock: Canopy Growth vs. Tilray Brands

Cannabis ETFs are garnering attention in 2024 as the industry shows promising growth. Key players like MJ, MSOS, and CNBS dominate this sector. These ETFs offer diversified exposure to cannabis-related stocks. This includes companies involved in cultivation, production, and retail. The U.S. cannabis industry has seen remarkable growth. Statistics reveal a projected market size of over $30 billion by 2025. This growth is fueled by expanding legalization and increased consumer acceptance. Investors are increasingly attracted to this sector for its high-growth potential. However, the industry faces regulatory challenges and market volatility.

Cultivating Wealth: 2024's Top Cannabis ETFs for Long Term Investors

SMITHS FALLS, ON , Jan. 18, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), today announced that it has entered into subscription agreements (the "Subscription Agreements"), dated as of January 18, 2024, with certain institutional investors (the "Investors") in a private placement offering (the "Offering") of 8,158,510 units ("Units") at a price per Unit of US$4.29 for aggregate gross proceeds of approximately US$35 million.  The purpose of the Offering is to provide the Company with additional liquidity to further strengthen Canopy Growth's financial position.

Canopy Growth Announces Upsized US$35 Million Private Placement

Cannabis should be one of the fastest-growing global industries for the remainder of the decade. Despite lofty growth prospects for the marijuana industry, legalization efforts in the U.S. have fallen flat.

3 Pot Stocks to Avoid Like the Plague in 2024

After announcing a $30 million sale of new stock and warrants last week, Canopy Growth terminated the deal

Why Canopy Growth Stock Rebounded Today

When volatility picks up on Wall Street, investors have a tendency to gravitate toward prominent companies enacting stock splits. Forward-stock splits have acted as a beacon for businesses that are out-innovating their competition.

The Once High-Flying Stock-Split Stock to Avoid Like the Plague in 2024

The last decade saw a trend for destigmatization of the use of psychoactive substances accompanied by a wave of legislation either legalizing or decriminalizing mostly marijuana-based products – both for medical and recreational use.

Marijuana stocks to watch in 2024

In the most recent trading session, Canopy Growth Corporation (CGC) closed at $4.56, indicating a -0.87% shift from the previous trading day.

Canopy Growth Corporation (CGC) Stock Drops Despite Market Gains: Important Facts to Note

Nasdaq

President Biden pardon of marijuana convictions has investors bullish on the prospects of marijuana legalization. But the process of legalization is by no means simple.

Investors Shouldn't Get Their Hopes Up for Marijuana Legalization in 2024: Here's Why

Canopy Growth is selling stock in order to raise funds. The new stock sale will take place at levels significantly below the stock's recent valuation.

Why Canopy Growth Stock Is Getting Smoked Again Today

Shares of cannabis specialist Canopy Growth (NASDAQ: CGC ) fell heavily on Tuesday following an eyebrow-raising announcement. Management disclosed that it entered a private placement agreement with select institutional investors.

Why Is Canopy Growth (CGC) Stock Down 8% Today?

Canopy Growth Corp.'s stock CGC, +6.11% WEED, +5.64% was down 13% to $4.45 a share in premarket trading on Tuesday after the company said it agreed to sell $30 million in units in a private placement with institutional investors. Canopy Growth said it OK'd the sale at a price of $4.29 per unit, which is below the stock's closing price of $5.04 a share on Monday.

Cannabis company Canopy Growth stock drops after $30M private placement at a discount price

SMITHS FALLS, ON , Jan. 9, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), today announced that it has entered into subscription agreements (the "Subscription Agreements"), dated as of January 9, 2024, with certain institutional investors (the "Investors") in a private placement offering (the "Offering") of 6,993,007 units ("Units") at a price per Unit of US$4.29 for aggregate gross proceeds of approximately US$30,000,000. The purpose of the Offering is to provide the Company with additional liquidity of US$30MM to further strengthen Canopy Growth's financial position.

Canopy Growth Announces US$30 Million Private Placement

Cannabis stocks are notching their second day of gains after the Drug Enforcement Administration confirmed it's reviewing an August recommendation from the U.S. Department of Health and Human Services (HHS) to change the classification of marijuana to Schedule III from Schedule I under the Controlled Substances Act. In a letter to Rep.

Cannabis stocks mark second day of gains as DEA confirms its review of marijuana's Schedule I classification

Village Farms International

As the global cannabis industry continues to expand, with its value reaching an impressive $50 billion in 2023, Canadian marijuana stocks are becoming increasingly important to watch in the first quarter of 2024. The early adoption of legalization in Canada has given its companies a significant advantage, allowing them to extend their influence worldwide. This rapid growth and international expansion make Canadian cannabis stocks a focal point for investors in the upcoming quarter.

Investor's Guide: Top Canadian Cannabis Stocks for Q1 2024

Canopy Growth deployed a 1-for-10 reverse stock split in late December. It's the first time the company has had to do so to keep its price above $1.

Why Canopy Growth's Reverse Split Marks a Turning Point for the Business

Canopy Growth just did a reverse stock split. The reverse split won't make generally poor sentiment about the stock any better.

1 Grim Tiding and 2 Silver Linings for Canopy Growth Stock in 2024

A new initiative from the White House injected a much-needed blast of hope throughout the sector. Although the move only affects Americans, it is rightly seen as positive for pot companies in Canada too.

News for Canopy Growth Stock (CGC)